These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23782251)

  • 1. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas.
    Hinton J; Callan R; Bodine C; Glasgow W; Brower S; Jiang SW; Li J
    Expert Rev Mol Diagn; 2013 Jun; 13(5):431-43. PubMed ID: 23782251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers.
    Fukushige S; Horii A
    Cancer Lett; 2014 Jan; 342(2):231-7. PubMed ID: 22450751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.
    Jiang B; Gu Y; Chen Y
    Cancer Invest; 2014 Jul; 32(6):218-25. PubMed ID: 24745611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic biomarkers in lung cancer.
    Liloglou T; Bediaga NG; Brown BR; Field JK; Davies MP
    Cancer Lett; 2014 Jan; 342(2):200-12. PubMed ID: 22546286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic biomarkers in laboratory diagnostics: emerging approaches and opportunities.
    Sandoval J; Peiró-Chova L; Pallardó FV; García-Giménez JL
    Expert Rev Mol Diagn; 2013 Jun; 13(5):457-71. PubMed ID: 23782253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers.
    Deng D; Liu Z; Du Y
    Adv Genet; 2010; 71():125-76. PubMed ID: 20933128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic biomarkers in prostate cancer: Current and future uses.
    Chiam K; Ricciardelli C; Bianco-Miotto T
    Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
    Syren P; Andersson R; Bauden M; Ansari D
    Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic biomarkers in colorectal cancer diagnostics.
    Rawson JB; Bapat B
    Expert Rev Mol Diagn; 2012 Jun; 12(5):499-509. PubMed ID: 22702366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma.
    Botezatu A; Bleotu C; Nastase A; Anton G; Bacalbasa N; Duda D; Dima SO; Popescu I
    Cancer Genomics Proteomics; 2015; 12(1):21-30. PubMed ID: 25560641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of epigenetic alterations in pancreatic cancer.
    Sato N; Goggins M
    J Hepatobiliary Pancreat Surg; 2006; 13(4):286-95. PubMed ID: 16858539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma.
    Cavallari I; Silic-Benussi M; Rende F; Martines A; Fogar P; Basso D; Vella MD; Pedrazzoli S; Herman JG; Chieco-Bianchi L; Esposito G; Ciminale V; D'Agostino DM
    Genes Chromosomes Cancer; 2009 May; 48(5):383-96. PubMed ID: 19170121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
    Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
    Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
    Tang JT; Wang JL; Du W; Hong J; Zhao SL; Wang YC; Xiong H; Chen HM; Fang JY
    Carcinogenesis; 2011 Aug; 32(8):1207-15. PubMed ID: 21665895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung cancer epigenetics: emerging biomarkers.
    Balgkouranidou I; Liloglou T; Lianidou ES
    Biomark Med; 2013 Feb; 7(1):49-58. PubMed ID: 23387484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ; Kim YJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in miR-143 and miR-21 expression and clinicopathological correlations in pancreatic cancers.
    Tavano F; di Mola FF; Piepoli A; Panza A; Copetti M; Burbaci FP; Latiano T; Pellegrini F; Maiello E; Andriulli A; di Sebastiano P
    Pancreas; 2012 Nov; 41(8):1280-4. PubMed ID: 22836856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.